Business Description
Concord Biotech Ltd
ISIN : INE338H01029
Total Employee Number:
2,782Compare
Compare
Traded in other countries / regions
543960.India IPO Date
2023-08-18Description
Concord Biotech Ltd is a bio-pharmaceutical company specializing in manufacturing Active Pharmaceutical Ingredients (APIs) and high-quality Finished formulations. It is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. The Company's API manufacturing facilities are located at Dholka and Limbasi, and its formulations facility at Valthera in the state of Gujarat, India. The Company is engaged in the business of manufacturing and trading in pharmaceutical products. The company has single operating segment. The company has presence in India, United States of America, and Others. The company generates majority of revenue from India. Its products are Active Pharmaceutical Ingredients, and Formulation.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 175.6 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-EBITDA | 0.01 | |||||
Interest Coverage | 1201.52 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 43.31 | |||||
Beneish M-Score | -2.18 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8 | |||||
3-Year EBITDA Growth Rate | 3.3 | |||||
3-Year EPS without NRI Growth Rate | 1.2 | |||||
3-Year FCF Growth Rate | 19.4 | |||||
3-Year Book Growth Rate | 16.1 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.58 | |||||
9-Day RSI | 66.02 | |||||
14-Day RSI | 63.51 | |||||
3-1 Month Momentum % | 10.97 | |||||
6-1 Month Momentum % | 1.6 | |||||
12-1 Month Momentum % | -18.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.39 | |||||
Quick Ratio | 5.46 | |||||
Cash Ratio | 2.4 | |||||
Days Inventory | 402.11 | |||||
Days Sales Outstanding | 151.33 | |||||
Days Payable | 143.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.53 | |||||
Dividend Payout Ratio | 0.37 | |||||
Forward Dividend Yield % | 0.53 | |||||
5-Year Yield-on-Cost % | 0.55 | |||||
Shareholder Yield % | 0.56 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 77.01 | |||||
Operating Margin % | 28.29 | |||||
Net Margin % | 24.65 | |||||
EBITDA Margin % | 39.63 | |||||
FCF Margin % | 15.49 | |||||
OCF Margin % | 24.08 | |||||
ROE % | 14.49 | |||||
ROA % | 13.03 | |||||
ROIC % | 14.78 | |||||
3-Year ROIIC % | 0.43 | |||||
ROC (Joel Greenblatt) % | 24.8 | |||||
ROCE % | 18.91 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 48.81 | |||||
Forward PE Ratio | 37 | |||||
PE Ratio without NRI | 48.42 | |||||
Price-to-Owner-Earnings | 60.4 | |||||
PEG Ratio | 5.15 | |||||
PS Ratio | 13.39 | |||||
PB Ratio | 7.35 | |||||
Price-to-Tangible-Book | 7.36 | |||||
Price-to-Free-Cash-Flow | 86.32 | |||||
Price-to-Operating-Cash-Flow | 55.54 | |||||
EV-to-EBIT | 39.55 | |||||
EV-to-EBITDA | 32.82 | |||||
EV-to-Revenue | 13.01 | |||||
EV-to-FCF | 83.95 | |||||
Price-to-GF-Value | 0.87 | |||||
Price-to-Peter-Lynch-Fair-Value | 6.45 | |||||
Price-to-Graham-Number | 4.3 | |||||
| Price-to-Net-Current-Asset-Value | 14.36 | |||||
| Price-to-Net-Cash | 78.46 | |||||
Earnings Yield (Greenblatt) % | 2.53 | |||||
FCF Yield % | 1.16 | |||||
Forward Rate of Return (Yacktman) % | 10.03 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Concord Biotech Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 11,083.921 | ||
| EPS (TTM) (₹) | 29.03 | ||
| Beta | 1.783 | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 40.27 | ||
| 14-Day RSI | 63.51 | ||
| 14-Day ATR (₹) | 50.055716 | ||
| 20-Day SMA (₹) | 1339.4525 | ||
| 12-1 Month Momentum % | -18.52 | ||
| 52-Week Range (₹) | 987.05 - 1800 | ||
| Shares Outstanding (Mil) | 104.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Concord Biotech Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Concord Biotech Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 7.550000 Cash Dividend | 2026-07-24 | 1,268.25 (-0.92%) | ||
| INR 10.700000 Cash Dividend | 2025-09-03 | 1,691.15 (-0.59%) |
Show
Entries
Concord Biotech Ltd Frequently Asked Questions
What is Concord Biotech Ltd(BOM:543960)'s stock price today?
The current price of BOM:543960 is ₹1416.95. The 52 week high of BOM:543960 is ₹1800.00 and 52 week low is ₹987.05.
When is next earnings date of Concord Biotech Ltd(BOM:543960)?
The next earnings date of Concord Biotech Ltd(BOM:543960) is .
Does Concord Biotech Ltd(BOM:543960) pay dividends? If so, how much?
The Dividend Yield %  of Concord Biotech Ltd(BOM:543960) is 0.53% (As of Today), Highest Dividend Payout Ratio of Concord Biotech Ltd(BOM:543960) was 0.46. The lowest was 0.26. And the median was 0.36. The  Forward Dividend Yield % of Concord Biotech Ltd(BOM:543960) is 0.53%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Concord Biotech Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers